Page 10 - Final Slides

Docetaxel in M1 CSPC: Survival (initial analysis)

Results based on 2993 men / 1254 deaths

Trial name

CHAARTED

GETUG15
STAMPEDE (SOC +/- Doc)

STAMPEDE (SOC+ZA +/- Doc)
Overall HR=0.77 (0.68, 0.87) p<0.0001

.5 1 2
Favours SOC + docetaxel Favours SOC

2
Heterogeneity: =4.80, df=3, p=0.187, I = 37.5%
2

10% absolute improvement in survival

(from 40% to 50%) at 4 years

Vale C, Lancet Oncol 2016;17:243-56